Precision treatment of beta-cell monogenic diabetes: a systematic review
Rochelle N Naylor,Kashyap A Patel,Jarno L T Kettunen,Jonna M E Männistö,Julie Støy,Jacques Beltrand,Michel Polak,ADA/EASD PMDI,Tina Vilsbøll,Siri A W Greeley,Andrew T Hattersley,Tiinamaija Tuomi,Deirdre K Tobias,Jordi Merino,Abrar Ahmad,Catherine Aiken,Jamie L Benham,Dhanasekaran Bodhini,Amy L Clark,Kevin Colclough,Rosa Corcoy,Sara J Cromer,Daisy Duan,Jamie L Felton,Ellen C Francis,Pieter Gillard,Véronique Gingras,Romy Gaillard,Eram Haider,Alice Hughes,Jennifer M Ikle,Laura M Jacobsen,Anna R Kahkoska,Raymond J Kreienkamp,Lee-Ling Lim,Robert Massey,Niamh-Maire Mclennan,Rachel G Miller,Mario Luca Morieri,Jasper Most,Bige Ozkan,Kashyap Amratlal Patel,Scott J Pilla,Katsiaryna Prystupa,Sridharan Raghavan,Mary R Rooney,Martin Schön,Zhila Semnani-Azad,Magdalena Sevilla-Gonzalez,Pernille Svalastoga,Wubet Worku Takele,Claudia Ha-Ting Tam,Anne Cathrine B Thuesen,Mustafa Tosur,Amelia S Wallace,Caroline C Wang,Jessie J Wong,Jennifer M Yamamoto,Katherine Young,Chloé Amouyal,Mette K Andersen,Maxine P Bonham,Mingling Chen,Feifei Cheng,Tinashe Chikowore,Sian C Chivers,Christoffer Clemmensen,Dana Dabelea,Adem Y Dawed,Aaron J Deutsch,Laura T Dickens,Linda A DiMeglio,Monika Dudenhöffer-Pfeifer,Carmella Evans-Molina,María Mercè Fernández-Balsells,Hugo Fitipaldi,Stephanie L Fitzpatrick,Stephen E Gitelman,Mark O Goodarzi,Jessica A Grieger,Marta Guasch-Ferré,Nahal Habibi,Torben Hansen,Chuiguo Huang,Arianna Harris-Kawano,Heba M Ismail,Benjamin Hoag,Randi K Johnson,Angus G Jones,Robert W Koivula,Aaron Leong,Gloria K W Leung,Ingrid M Libman,Kai Liu,S Alice Long,William L Lowe Jr,Robert W Morton,Ayesha A Motala,Suna Onengut-Gumuscu,James S Pankow,Maleesa Pathirana,Sofia Pazmino,Dianna Perez,John R Petrie,Camille E Powe,Alejandra Quinteros,Rashmi Jain,Debashree Ray,Mathias Ried-Larsen,Zeb Saeed,Vanessa Santhakumar,Sarah Kanbour,Sudipa Sarkar,Gabriela S F Monaco,Denise M Scholtens,Elizabeth Selvin,Wayne Huey-Herng Sheu,Cate Speake,Maggie A Stanislawski,Nele Steenackers,Andrea K Steck,Norbert Stefan,Rachael Taylor,Sok Cin Tye,Gebresilasea Gendisha Ukke,Marzhan Urazbayeva,Bart Van der Schueren,Camille Vatier,John M Wentworth,Wesley Hannah,Sara L White,Gechang Yu,Yingchai Zhang,Shao J Zhou,Ingvild Aukrust,Elisa de Franco,Sarah E Flanagan,Kristin A Maloney,Andrew McGovern,Janne Molnes,Mariam Nakabuye,Pål Rasmus Njølstad,Hugo Pomares-Millan,Michele Provenzano,Cécile Saint-Martin,Cuilin Zhang,Yeyi Zhu,Sungyoung Auh,Russell de Souza,Andrea J Fawcett,Chandra Gruber,Eskedar Getie Mekonnen,Emily Mixter,Diana Sherifali,Robert H Eckel,John J Nolan,Louis H Philipson,Rebecca J Brown,Liana K Billings,Kristen Boyle,Tina Costacou,John M Dennis,Jose C Florez,Anna L Gloyn,Maria F Gomez,Peter A Gottlieb,Siri Atma W Greeley,Kurt Griffin,Irl B Hirsch,Marie-France Hivert,Korey K Hood,Jami L Josefson,Soo Heon Kwak,Lori M Laffel,Siew S Lim,Ruth J F Loos,Ronald C W Ma,Chantal Mathieu,Nestoras Mathioudakis,James B Meigs,Shivani Misra,Viswanathan Mohan,Rinki Murphy,Richard Oram,Katharine R Owen,Susan E Ozanne,Ewan R Pearson,Wei Perng,Toni I Pollin,Rodica Pop-Busui,Richard E Pratley,Leanne M Redman,Maria J Redondo,Rebecca M Reynolds,Robert K Semple,Jennifer L Sherr,Emily K Sims,Arianne Sweeting,Miriam S Udler,Kimberly K Vesco,Robert Wagner,Stephen S Rich,Paul W Franks
DOI: https://doi.org/10.1038/s43856-024-00556-1
2024-07-18
Abstract:Background: Beta-cell monogenic forms of diabetes have strong support for precision medicine. We systematically analyzed evidence for precision treatments for GCK-related hyperglycemia, HNF1A-, HNF4A- and HNF1B-diabetes, and mitochondrial diabetes (MD) due to m.3243 A > G variant, 6q24-transient neonatal diabetes mellitus (TND) and SLC19A2-diabetes. Methods: The search of PubMed, MEDLINE, and Embase for individual and group level data for glycemic outcomes using inclusion (English, original articles written after 1992) and exclusion (VUS, multiple diabetes types, absent/aggregated treatment effect measures) criteria. The risk of bias was assessed using NHLBI study-quality assessment tools. Data extracted from Covidence were summarized and presented as descriptive statistics in tables and text. Results: There are 146 studies included, with only six being experimental studies. For GCK-related hyperglycemia, the six studies (35 individuals) assessing therapy discontinuation show no HbA1c deterioration. A randomized trial (18 individuals per group) shows that sulfonylureas (SU) were more effective in HNF1A-diabetes than in type 2 diabetes. Cohort and case studies support SU's effectiveness in lowering HbA1c. Two cross-over trials (each with 15-16 individuals) suggest glinides and GLP-1 receptor agonists might be used in place of SU. Evidence for HNF4A-diabetes is limited. Most reported patients with HNF1B-diabetes (N = 293) and MD (N = 233) are on insulin without treatment studies. Limited data support oral agents after relapse in 6q24-TND and for thiamine improving glycemic control and reducing/eliminating insulin requirement in SLC19A2-diabetes. Conclusion: There is limited evidence, and with moderate or serious risk of bias, to guide monogenic diabetes treatment. Further evidence is needed to examine the optimum treatment in monogenic subtypes.